Goldman Sachs recommends Sarepta ahead of ‘key’ Q1 catalyst

Goldman Sachs analyst Salveen Richter said he recommends Sarepta shares ahead of key Q1 catalyst — the MYO-101 Ph1/2 limb girdle muscular dystrophy 60-day biopsy data. Richter added that Sarepta is positioned for a strong year in 2019, as he looks to execution across multiple fronts, including selective BD to drive the R&D engine, golodirsen US approval around Q3, casimersen dystrophin expression data with a potential filing in the middle of the year, SRP-5051 Ph1 data by year end, and additional gene therapy trial progress. The analyst maintained a Buy rating and $191 price target on Sarepta.
https://thefly.com/landingPageNews.php?id=2845631